ZyVersa Therapeutics, Inc.
ZVSA evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ZVSA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ZVSA
ZyVersa Therapeutics is a clinical-stage biopharmaceutical company developing first-in-class drugs for renal and inflammatory diseases, with lead candidates VAR 200 for focal segmental glomerulosclerosis (FSGS) and IC 100 for inflammasome-related conditions.
Key risk: Cash runway risk
BioSniper Score
Based on 4 of 6 signals
Financial data as of Mar 31, 2026.
Tracking 2 pipeline candidates · 1 clinical trial for ZyVersa Therapeutics, Inc..
ZyVersa Therapeutics is a clinical-stage biopharmaceutical company developing first-in-class drugs for renal and inflammatory diseases, with lead candidates VAR 200 for focal segmental glomerulosclerosis (FSGS) and IC 100 for inflammasome-related conditions.
- ZyVersa is a clinical-stage specialty biopharmaceutical company developing first-in-class drugs for renal and inflammatory diseases with high unmet medical needs [sec_mda · as of 2026-05-13].
- Lead renal candidate VAR 200 (2-hydroxypropyl-beta-cyclodextrin) targets multiple renal indications, with focal segmental glomerulosclerosis (FSGS) as the lead indication [sec_mda · as of 2026-05-13].
- Lead anti-inflammatory candidate IC 100 is a humanized monoclonal IgG4 antibody targeting ASC, with obesity and cardiometabolic comorbidities as the lead indication [sec_mda · as of 2025-08-13].
- As of 2026-03-31, the company reported cash & equivalents of $0.3M, net income of -$1.8M, and shareholders' equity of $8.5M [sec].
- The company has not generated any revenue to date and has incurred significant operating losses [sec_mda · as of 2025-05-12].
What works
- ZyVersa's pipeline includes two first-in-class candidates (VAR 200 and IC 100) each offering a 'pipeline within a product' with potential for multiple indications, addressing a total accessible market over $100 billion [sec_mda · as of 2024-11-14].
- The company is positioned in the rapidly emerging inflammasome space with a highly differentiated monoclonal antibody (IC 100) [sec_mda · as of 2024-11-14].
- ZyVersa plans to evaluate strategic transactions to acquire or in-license approved or development products to augment its pipeline [sec_mda · as of 2026-05-13].
What to weigh
- ZyVersa has not generated any revenue to date and has incurred significant operating losses [sec_mda · as of 2025-05-12].
- As of 2026-03-31, the company had only $0.3M in cash & equivalents, which may limit its ability to fund ongoing operations and clinical development without additional financing [sec].
- The company expects to incur significant costs to comply with corporate governance, internal controls, and public company requirements [sec_mda · as of 2026-05-13].
- Future capital requirements depend on many forward-looking factors, including the initiation, progress, timing, costs, and results of clinical trials, which are uncertain [sec_mda · as of 2026-05-13].
From the filings
Quoted directly from source documents.
ZyVersa is a clinical-stage specialty biopharmaceutical company developing first-in-class drugs for renal and inflammatory diseases.
“We are a clinical stage specialty biopharmaceutical company leveraging advanced proprietary technologies to develop first-in-class drugs for patients with renal or inflammatory diseases with high unmet medical needs.”
SEC MD&A · May 13, 2026
Lead renal candidate VAR 200 targets FSGS as the lead indication.
“Our renal drug candidate, which we refer to as Cholesterol Efflux Mediator TM VAR 200 (2-hydroxypropyl-beta-cyclodextrin or "2HβCD"), is in development to treat multiple renal indications. The lead indication is focal segmental glomerulosclerosis (FSGS).”
SEC MD&A · May 13, 2026
The company has not generated any revenue and has incurred significant operating losses.
“We have not generated any revenue to date and have incurred significant operating lo”
SEC MD&A · May 12, 2025
Risks & what to watch (4)›
Key risks
- Cash runway risk — Cash & equivalents of only $0.3M as of 2026-03-31 may be insufficient to fund operations without additional financing [sec].
- No revenue generation — The company has not generated any revenue to date and has incurred significant operating losses [sec_mda · as of 2025-05-12].
- Clinical development uncertainty — Future capital requirements depend on the initiation, progress, timing, costs, and results of clinical trials, which are uncertain [sec_mda · as of 2026-05-13].
- Regulatory and compliance costs — Expects significant costs to comply with corporate governance, internal controls, and public company requirements [sec_mda · as of 2026-05-13].
What to watch
- Progress and results of clinical development plans and trials for VAR 200 and IC 100 [sec_mda · as of 2026-05-13].
- Any strategic transactions, including in-licensing or acquisition of product candidates, that could affect liquidity and capital resources [sec_mda · as of 2026-05-13].
- The company's ability to secure additional financing given its low cash position [sec].
- Updates on the lead indications for VAR 200 (FSGS) and IC 100 (obesity with cardiometabolic comorbidities) [sec_mda · as of 2026-05-13].
Sources: SEC MD&A · Generated August 10, 2026 · How we verify sources →
Run ZyVersa Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ZyVersa Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
1.6 months
OCF -$799K · Net income -$2M
Lead: Preclinical
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Jun 2025Institutional holders
7
Total value held
$45K
| Holder | Shares | Value |
|---|---|---|
| ubs group ag | 39,280 | $27K |
| geode capital management, llc | 21,706 | $15K |
| tower research capital llc (trc) | 4,525 | $3K |
| citigroup inc | 274 | $186 |
| sbi securities co., ltd. | 151 | $102 |
| bank of america corp /de/ | 132 | $90 |
| concourse financial group securities, inc. | 0 | $0 |
Short Interest
as of Apr 22, 2026- % of float
- 7.4%
- Days to cover
- 0.3
- Shares short
- 359,252
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ZVSA short interestGovernance
Frequently asked questions
What is the AI investment thesis for ZyVersa Therapeutics, Inc.?
ZyVersa Therapeutics is a clinical-stage biopharmaceutical company developing first-in-class drugs for renal and inflammatory diseases, with lead candidates VAR 200 for focal segmental glomerulosclerosis (FSGS) and IC 100 for inflammasome-related conditions.
What is ZyVersa Therapeutics, Inc.'s lead drug candidate?
ZyVersa Therapeutics, Inc.'s most advanced tracked candidate is ic 100 (Preclinical) for Obesity with metabolic complications.
Who is the CEO of ZyVersa Therapeutics, Inc.?
Mr. Stephen C. Glover is the chief executive officer of ZyVersa Therapeutics, Inc. (ZVSA).
Where is ZyVersa Therapeutics, Inc. headquartered?
ZyVersa Therapeutics, Inc. (ZVSA) is headquartered in Weston, FL, United States.
What therapeutic areas does ZyVersa Therapeutics, Inc. focus on?
ZyVersa Therapeutics, Inc. develops therapies across Metabolic, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.